尽管收入被打折扣,但斯托克治疗学降低了2025年EPS预测值,尽管损失和输油管道问题重重。 Stoke Therapeutics lowered 2025 EPS forecasts amid losses and pipeline issues, despite revenue beat.

华因赖特和菲茨杰拉德分别将斯托克治疗公司的2025年EPS估计降至0.04美元和0.03美元,理由是持续的管道挑战和最近的季度收益缺失,该公司报告每股0.65美元的亏损,低于0.54美元的共识. HC Wainwright and Cantor Fitzgerald lowered their 2025 EPS estimates for Stoke Therapeutics to $0.04 and $0.03, respectively, citing ongoing pipeline challenges and a recent quarterly earnings miss, with the company reporting a $0.65 loss per share, below the $0.54 consensus. 尽管收入为1 063万美元,超过估计,但该公司继续亏损运作,全年损失预计持续到2027年。 Despite revenue of $10.63 million, surpassing estimates, the firm continues to operate at a loss, with full-year losses projected through 2027. 股价为22.47美元,市场上限为12.8亿美元,具有协商一致的“购买模式”评级和31.00美元的目标,尽管一些分析家维持目标更高的“购买”评级。 The stock, trading at $22.47 with a $1.28 billion market cap, has a consensus "Moderate Buy" rating and a $31.00 target, though some analysts maintain "buy" ratings with higher targets. 内幕销售和混合机构活动反映出投资者的谨慎态度。 Insider selling and mixed institutional activity reflect cautious investor sentiment.